Big pharma--bullies in the PBS: Hans Lofgren shows how US pharmaceutical companies are undermining the PBS.(Pharmaceutical Benefits Scheme)Lofgren, Hans
But what’s the point if the fines are small relative to the profits, if the wrong people are feeling the financial pinch, and if no executive is held accountable? The only way to get big companies like these to change their behavior is to make the individuals responsible feel the heat. ...
We know that companies earn big money by funding R&D projects. But how much do the scientists who put in the actual work make? The last few years have seen tremendous growth in the global pharmaceutical market, ending last year at a valuation of $1.25 trillion.The industry was valued at $...
It’s easy to focus on just premiums when looking at how much a plan can cost. Premiums are regular monthly expenses that must fit into a budget, and most of us are keenly aware of our monthly expenses. But it’s a better idea to look at the big picture — to look at all of you...
their growth objective if they rely too heavily on their internal R&D alone. Taking an ecosystem approach that fosters alliances and M&A with companies producing early-stage products, digital investing and technology can help close the innovation gap that big biopharmas might face in the coming ...
It goes like this: A cure for cancer exists, but pharmaceutical companies — and perhaps even government health agencies and cancer charities — are suppressing it because they make so much money from treating the disease or fundraising for it. In other words, a secret cabal of pharma execs,...
Brand equity is a measure of the perceived worth of a brand or product in the eyes of consumers. Learn how to build and strengthen your brand’s equity.
"Commodities, as a whole, tend to perform better in a rising-rate environment than in a falling-rate environment," he says. "In particular, energy and industrial metals commodities have historically performed much better when rates are rising than when they are falling." ...
— Being the one public plan, it will have large economies of scale that will enable it to negotiate more favorable terms with pharmaceutical companies and other providers. (Here, he must clear up any confusion about any deal made with Big Pharma.) But this won’t lead to a government tak...
PBMs were initially created to reduce drug costs by negotiating prices with pharmaceutical manufacturers. In the late 1980s and early 1990s, these companies worked by pooling purchasing power and leveraging it to the benefit of healthcare consumers. It didn’t take long, however, until ...